The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions

Pain

Volumn 105, Issue 1-2, 2003, Pages 79-88

  Naef, Myrtha ^a   Curatolo, Michele ^b   Petersen Felix, Steen ^b   Arendt Nielsen, Lars ^c   Zbinden, Alex ^b   Brenneisen, Rudolf ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c AALBORG UNIVERSITY   (Denmark)

Author keywords

Antinociception; Delta 9 tetrahydrocannabinol; Experimental pain; Morphine; Pharmacokinetics; Plasma levels

Indexed keywords

DRONABINOL; MORPHINE; PLACEBO;

ACUTE STRESS DISORDER; ADULT; AGGRESSIVENESS; ANALGESIC ACTIVITY; ANTINOCICEPTION; ARTICLE; BIOLOGICAL MONITORING; BLOOD SAMPLING; CLINICAL TRIAL; COLD EXPOSURE; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DYSPNEA; ELECTROSTIMULATION; EUPHORIA; FEMALE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEAT TOLERANCE; HUMAN; HYPERALGESIA; IRRITABILITY; MALE; MEASUREMENT; NAUSEA; NORMAL HUMAN; OBSERVATION; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TACHYCARDIA; VERTIGO; VISUAL ANALOG SCALE; VOMITING; XEROSTOMIA;

EID: 0141515748     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(03)00163-5     Document Type: Article

References (52)

1. Arendt-Nielsen L., Brennum J., Sindrup S., Bak P. Electrophysiological and psychophysical quantification of temporal summation in the human nociceptive system. Eur J Appl Physiol Occup Physiol. 68:1994;266-273.
2. Arendt-Nielsen L., Nielsen J., Petersen-Felix S., Schnider T.W., Zbinden A.M. Effect of racemic mixture and the (S+)-isomer of ketamine on temporal and spatial summation of pain. Br J Anaesth. 77:1996;625-631.
3. Bourquin D., Bundeli P., Lehmann T., Brenneisen R. Diacetylmorphine and its metabolites in plasma by HPLC with diode-array and atmospheric pressure ionization mass spectrometric detection. J Liq Chromatogr Rel Technol. 22:1999;2663-2674.
4. Brenneisen R. Pharmacokinetics. Grotenhermen F., Russo E. Cannabis and cannabinoids. 2002;67-72 Haworth Press, Binghamton, NY.
5. Brenneisen R., Egli A., ElSohly M.A., Henn V., Spiess Y. The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with two patients. Int J Clin Pharmacol Ther. 34:1996;446-452.
6. Brennum J., Kjeldsen M., Jensen K., Jensen T.S. Measurements of human pressure-pain thresholds on fingers and toes. Pain. 38:1989;211-217.
7. Brennum J., Arendt-Nielsen L., Secher N.H., Jensen T.S., Bjerring P. Quantitative sensory examination in human epidural anaesthesia and analgesia: effects of lidocaine. Pain. 51:1992;27-34.
8. Buetler T.M., Wilder-Smith O.H., Wilder-Smith C.H., Aebi S., Cerny T., Brenneisen R. Analgesic action of i.v. morphine-6-glucuronide in healthy volunteers. Br J Anaesth. 84:2000;97-99.
9. Campbell F.A., Tramèr M.R., Carroll D., Reynolds D.J.M., Moore R.A., McQuay H.J. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Br Med J. 323:2001;13-16.
10. Cichewicz D.L., Martin Z.I., Smith F.L., Welch S.P. Enhancement of μ opioid antinociception by oral Δ9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther. 289:1999;859-867.
11. Clark W.C., Janal M.N., Zeidenberg P., Nahas G.G. Effects of moderate and high doses of marihuana on thermal pain: a sensory decision theory analysis. J Clin Pharmacol. 21:1981;299S-310S.
12. Curatolo M., Petersen-Felix S., Gerber A., Arendt-Nielsen L. Remifentanil inhibits muscular more than cutaneous pain in humans. Br J Anaesth. 85:2000;529-532.
13. Elsner F., Radbruch L., Sabatowski R. Tetrahydrocannabinol zur Therapie chronischer Schmerzen (Tetrahydrocannabinol for treatment of chronic pain). Schmerz. 15:2001;200-204.
14. Enggaard T.P., Poulsen L., Arendt-Nielsen L., Hansen S.H., Bjornsdottir I., Gram L.F., Sindrup S.H. The analgesic effect of codeine as compared to imipramine in different human experimental pain models. Pain. 92:2001;277-282.
15. Feng S., ElSohly M.A., Salamone S., Salem M.Y. Simultaneous analysis of delta-9-THC and its major metabolites in urine, plasma, and meconium by GC-MS using an immunoaffinity extraction procedure. J Anal Toxicol. 24:2000;395-402.
16. Fruhstorfer H., Lindblom U., Schmidt W.C. Method for quantitative estimation of thermal thresholds in patients. J Neurol Neurosurg Psychiatry. 39:1976;1071-1075.
17. Gralla R.J. Cannabinoids and the control of chemotherapy-induced nausea and vomiting. Nahas G.G., Sutin K.M., Harvey D.J., Agurell S. Marihuana and medicine. 1999;599-610 Humana Press Inc, Totowa, NJ.
18. Greenwald M.K., Stitzer M.L. Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend. 59:2000;261-275.
19. Grinspoon L., Bakalar J.B. Marihuana, the forbidden medicine. 1997;Yale University Press, New Haven/London.
20. Gyr E., Brenneisen R., Bourquin D., Lehmann T., Vonlanthen D., Hug I. Pharmacodynamics and pharmacokinetics of intravenously, orally and rectally administered diacetylmorphine in opioid dependents, a two-patient pilot study within a heroin-assisted treatment program. Int J Clin Pharmacol Ther. 38:2000;486-491.
21. Harvey D.J. Absorption, distribution, and biotransformation of the cannabinoids. Nahas G.G., Sutin K.M., Harvey D.J., Agurell S. Marihuana and medicine. 1999;91-103 Humana Press Inc, Totowa, NJ.
22. Hill S.Y., Schwin R., Goodwin D.W., Powell B.J. Marihuana and pain. J Pharmacol Exp Ther. 188:1974;415-418.
23. Holdcroft A., Smith M., Jacklin A., Hodgson H., Smith B., Newton M., Evans F. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia. 52:1997;483-486.
24. Jones S.F., McQuay H.J., Moore R.A., Hand C.W. Morphine and ibuprofen compared using the cold pressor test. Pain. 34:1988;117-122.
25. Joy J.E., Watson S.J., Benson J.A. Marijuana and medicine: assessing the science base. 1999;National Academy Press, Washington, DC.
26. Lichtman A.H., Martin B.R. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats. Pharmacol Biochem Behav. 57:1997;7-12.
27. Luginbuhl M., Schnider T.W., Petersen-Felix S., Arendt-Nielsen L., Zbinden A.M. Comparison of five experimental pain tests to measure analgesic effects of alfentanil. Anesthesiology. 95:2001;22-29.
28. Mechoulam R., Parker L.A., Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. 42:2002;11S-19S.
29. Milstein S.L., MacCannell K., Karr G., Clark S. Marijuana-produced changes in pain tolerance. Experienced and non-experienced subjects. Intern Pharmacopsych. 10:1975;177-182.
30. Notcutt W, Price M, Miller R, Newport S, Sansom C, Simmonds S. Medicinal cannabis extracts in chronic pain (4) - cannabidiol modification of psycho-active effects of delta-9-THC. Proceed 2001 Symposium on the cannabinoids, San Lorenzo de El Escorial, Spain; Burlington VT: International Cannabinoid Research Society (ICRS), p. 158.
31. Noyes R.J., Brunk S.F., Baram D.A., Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol. 15:1975;139-143.
32. Noyes R.J., Brunk S.F., Baram D.A., Canter A. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther. 18:1975;84-89.
33. Ogborne A.C., Smart R.G., Weber T., Birchmore-Timney C. Who is using cannabis as a medicine and why: an exploratory study. J Psychoactive Drugs. 32:2000;435-443.
34. Partland J.M., Russo E.B. Cannabis and Cannabis extracts: greater than the sum of their parts? J Cann Ther. 1:2001;103-132.
35. Pertwee R.G. Cannabinoid receptors and pain. Prog Neurobiol. 63:2001;569-611.
36. Petersen-Felix S., Arendt-Nielsen L., Bak P., Bjerring P., Breivik H., Svensson P., Zbinden A.M. Ondansetron does not inhibit the analgesic effect of alfentanil. Br J Anaesth. 73:1994;326-330.
37. Petersen-Felix S., Luginbuhl M., Schnider T.W., Curatolo M., Arendt-Nielsen L., Zbinden A.M. Comparison of the analgesic potency of xenon and nitrous oxide in humans evaluated by experimental pain. Br J Anaesth. 81:1998;742-747.
38. Raft D., Gregg J., Ghia J., Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. Clin Pharmacol Ther. 21:1977;26-36.
39. Siegling A., Hofmann H.A., Denzer D., Mauler F., De Vry J. Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol. 415:2001;R5-R7.
40. Sindrup S.H., Poulsen L., Brosen K., Arendt-Nielsen L., Gram L.F. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? Pain. 53:1993;335-339.
41. Smith F.L., Cichewicz D., Martin Z.L., Welch S.P. The enhancement of morphine antinociception in mice by Δ9-tetrahydrocannabinol. Pharmacol Biochem Behav. 60:1998;559-566.
42. Smith F.L., Fujimori K., Lowe J., Welch S.P. Characterization of Δ-9-THC and anandamide antinociception in non-arthritic and arthritic rats. Pharmacol Biochem Behav. 60:1998;183-191.
43. Soderpalm A.H., Schuster A., de Wit H. Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac. Pharmacol Biochem Behav. 69:2001;343-350.
44. Tramèr M.R., Carroll D., Campbell F.A., Reynolds D.J.M., Moore R.A., McQuay H.J. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. Br Med J. 323:2001;16-21.
45. ® (Dronabinol), Product Information Rev 10/2002, Marietta, GA (www.unimed.com) Physicians information for Marinol (dronabinol). Deerfield, IL, 2001.
46. Vivian J.A., Kishioka S., Butelman E.R., Broadbear J., Lee K.O., Woods J.H. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A. J Pharmacol Exp Ther. 286:1998;697-703.
47. Von Graffenried B., Adler R., Abt K., Nuesch E., Spiegel R. The influence of anxiety and pain sensitivity on experimental pain in man. Pain. 4:1978;253-263.
48. Wachtel S.R., ElSohly M.A., Ross S.A., Ambre J., de Wit H. Comparison of the subjective effects of delta-9-tetrahydrocannabinol and marijuana in humans. Psychopharmacology. 161:2002;331-339.
49. Wall M.E., Sadler B.M., Brine D., Taylor H., Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther. 34:1983;352-363.
50. Zeidenberg P., Crawford C.W., Jeffe J., Anderson S.W., Chin S., Malitz S. Effect of oral administration of delta-9-tetrahydrocannabinol on memory, speech, and perception of thermal stimulation: results with four normal human volunteer subjects. Preliminary report. Compr Psychiatry. 14:1973;549-556.
51. Zuardi A.W., Shirakawa I., Finkelfarb E., Karniol I.G. Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psychopharmacology. 76:1982;245-250.
52. Zuardi A.W., Morais S.L., Guimarães F.S., Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry. 56:1995;485-486.